NCT01428089View on ClinicalTrials.gov

Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 11, 2011

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Polycystic Ovary SyndromeHyperandrogenismNormal Puberty
Interventions
DRUG

Progesterone

Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.

DRUG

Placebo

Placebo

Trial Locations (1)

22908

RECRUITING

Center for Research in Reproduction, University of Virginia, Charlottesville

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of Virginia

OTHER